Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEARCH: Sorafenib plus Erlotinib in HCC
NCT00901901Phase 3Completed
- Sponsor
- Bayer
- Start
- May 2009
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 26
01
Overview
A Phase 3 trial of erlotinib in hepatocellular carcinoma (HCC), sponsored by Bayer. Started May 2009; status: completed.
02
Drugs
erlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00901901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00901901.